CN103874487A - R(+)-n-甲酰-炔丙基-氨基茚满 - Google Patents

R(+)-n-甲酰-炔丙基-氨基茚满 Download PDF

Info

Publication number
CN103874487A
CN103874487A CN201280049741.8A CN201280049741A CN103874487A CN 103874487 A CN103874487 A CN 103874487A CN 201280049741 A CN201280049741 A CN 201280049741A CN 103874487 A CN103874487 A CN 103874487A
Authority
CN
China
Prior art keywords
rasagiline
pharmaceutical composition
formyl
propargyl
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280049741.8A
Other languages
English (en)
Chinese (zh)
Inventor
穆罕默德·萨法迪
安东·弗兰克尔
迈克尔·凯撒
丹尼特·李驰特
埃泽尔·巴哈尔
拉米·林多尔-哈达斯
玛瑞娜·佐尔夫斯基
雷切尔·科恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN103874487A publication Critical patent/CN103874487A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/03—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to hydrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201280049741.8A 2011-10-10 2012-10-09 R(+)-n-甲酰-炔丙基-氨基茚满 Pending CN103874487A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161545422P 2011-10-10 2011-10-10
US61/545,422 2011-10-10
PCT/US2012/059356 WO2013055687A2 (en) 2011-10-10 2012-10-09 R(+)-n-formyl-propargyl-aminoindan

Publications (1)

Publication Number Publication Date
CN103874487A true CN103874487A (zh) 2014-06-18

Family

ID=48042235

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280049741.8A Pending CN103874487A (zh) 2011-10-10 2012-10-09 R(+)-n-甲酰-炔丙基-氨基茚满

Country Status (15)

Country Link
US (1) US9346746B2 (cg-RX-API-DMAC7.html)
EP (1) EP2766002A4 (cg-RX-API-DMAC7.html)
JP (1) JP2014534196A (cg-RX-API-DMAC7.html)
KR (1) KR20140090996A (cg-RX-API-DMAC7.html)
CN (1) CN103874487A (cg-RX-API-DMAC7.html)
AR (1) AR088297A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012323349A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014008555A2 (cg-RX-API-DMAC7.html)
CA (1) CA2851276A1 (cg-RX-API-DMAC7.html)
EA (1) EA201490761A1 (cg-RX-API-DMAC7.html)
HK (1) HK1200315A1 (cg-RX-API-DMAC7.html)
IL (1) IL231721A0 (cg-RX-API-DMAC7.html)
MX (1) MX2014004308A (cg-RX-API-DMAC7.html)
WO (1) WO2013055687A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201403043B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007217349B9 (en) * 2006-02-21 2013-06-27 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Multiple System Atrophy
CA2646250A1 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
PT2101569E (pt) * 2006-12-14 2012-01-13 Teva Pharma Base de rasagilina sólida cristalina
KR20100107028A (ko) * 2008-01-11 2010-10-04 테바 파마슈티컬 인더스트리즈 리미티드 라사길린 제형, 그들의 제법 및 용도
EP2285214B1 (en) * 2008-06-10 2012-05-16 Teva Pharmaceutical Industries Ltd. Rasagiline soft gelatin capsules
PL2451771T3 (pl) 2009-07-09 2014-12-31 Ratiopharm Gmbh Sole rasagiliny i ich preparaty farmaceutyczne
WO2011042812A1 (en) * 2009-10-09 2011-04-14 Stefan Lorenzl Use of rasagiline for the treatment of progressive supranuclear palsy
MX2012007375A (es) * 2009-12-22 2012-07-30 Teva Pharma 3-ceto-n-propargil 1-aminoindano.
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
AU2012323351A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-methyl-propargyl-aminoindan
WO2014028868A1 (en) 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulation of rasagiline

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012583A2 (en) * 1995-09-20 1997-04-10 Teva Pharmaceutical Industries Ltd. Stable compositions containing n-propargyl-1-aminoindan
US5877221A (en) * 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US6492426B1 (en) * 1999-10-27 2002-12-10 Teva Pharmaceutical Industries, Ltd. Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
US20110152381A1 (en) * 2009-12-22 2011-06-23 Anton Frenkel 3-keto-n-propargyl-1-aminoindan

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201470A (en) * 1965-08-17 Chsx c cech
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
ATE346598T1 (de) * 1994-01-10 2006-12-15 Teva Pharma 1-aminoindanderivate und zusammensetzungen hiervon
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
DK0966435T3 (da) 1996-12-18 2005-08-15 Teva Pharma Aminoindanderivater
EP1567152B1 (en) 2002-11-15 2013-08-14 Teva Pharmaceutical Industries Limited Use of rasagiline with riluzole to treat amyotrophic lateral sclerosis
US7619077B2 (en) 2003-02-06 2009-11-17 University Of Georgia Research Foundation Nucleic acids encoding a galacturonosyl tranferase enzyme (GALAT1) from arabidopsis
EP1778196A4 (en) 2004-07-26 2008-12-17 Teva Pharma PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
US20090111892A1 (en) 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
US7815942B2 (en) 2005-02-23 2010-10-19 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
US7491847B2 (en) 2005-11-17 2009-02-17 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
AU2007217349B9 (en) 2006-02-21 2013-06-27 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Multiple System Atrophy
CA2646250A1 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
PT2101569E (pt) 2006-12-14 2012-01-13 Teva Pharma Base de rasagilina sólida cristalina
EA016843B1 (ru) 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Таннат разагилина
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
KR20100107028A (ko) 2008-01-11 2010-10-04 테바 파마슈티컬 인더스트리즈 리미티드 라사길린 제형, 그들의 제법 및 용도
EP2285214B1 (en) 2008-06-10 2012-05-16 Teva Pharmaceutical Industries Ltd. Rasagiline soft gelatin capsules
BRPI0909894A2 (pt) 2008-06-13 2015-07-28 Teva Pharma "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica.
US7968749B2 (en) 2008-06-19 2011-06-28 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
AU2009260733B2 (en) 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
PL2451771T3 (pl) 2009-07-09 2014-12-31 Ratiopharm Gmbh Sole rasagiliny i ich preparaty farmaceutyczne
WO2011042812A1 (en) 2009-10-09 2011-04-14 Stefan Lorenzl Use of rasagiline for the treatment of progressive supranuclear palsy
CN102048717B (zh) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
EP2603212A4 (en) 2010-07-27 2014-01-08 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF SMOKING DISORDER
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
BR112013010308A2 (pt) 2010-10-26 2016-07-05 Teva Pharma rasagilina de deutério enriquecido
AU2012323351A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-methyl-propargyl-aminoindan
US20130089611A1 (en) 2011-10-10 2013-04-11 Teva Pharmaceutical Industries, Ltd. Rasagiline citramide
WO2014028868A1 (en) 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulation of rasagiline

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877221A (en) * 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
WO1997012583A2 (en) * 1995-09-20 1997-04-10 Teva Pharmaceutical Industries Ltd. Stable compositions containing n-propargyl-1-aminoindan
US6492426B1 (en) * 1999-10-27 2002-12-10 Teva Pharmaceutical Industries, Ltd. Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
US20110152381A1 (en) * 2009-12-22 2011-06-23 Anton Frenkel 3-keto-n-propargyl-1-aminoindan

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TARA SINGH等: "Antimalarials. 7-Chloro-4-(substituted amino）quinolines", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 14, no. 4, 31 December 1971 (1971-12-31), XP002337637, DOI: 10.1021/jm00286a003 *
张青山: "《有机合成反应基础》", 31 December 2004, 高等教育出版社, article "用羧酸的N-酰化" *

Also Published As

Publication number Publication date
KR20140090996A (ko) 2014-07-18
WO2013055687A2 (en) 2013-04-18
ZA201403043B (en) 2015-08-26
BR112014008555A2 (pt) 2017-04-18
EP2766002A4 (en) 2015-07-01
HK1200315A1 (en) 2015-08-07
IL231721A0 (en) 2014-05-28
AU2012323349A1 (en) 2014-05-22
AR088297A1 (es) 2014-05-21
MX2014004308A (es) 2014-07-24
US20130089612A1 (en) 2013-04-11
EA201490761A1 (ru) 2014-11-28
NZ624206A (en) 2016-11-25
CA2851276A1 (en) 2013-04-18
US9346746B2 (en) 2016-05-24
WO2013055687A3 (en) 2013-07-25
JP2014534196A (ja) 2014-12-18
EP2766002A2 (en) 2014-08-20

Similar Documents

Publication Publication Date Title
CN103874487A (zh) R(+)-n-甲酰-炔丙基-氨基茚满
CN103930100A (zh) R(+)-n-甲基-炔丙基-氨基茚满
CN103857389A (zh) 雷沙吉兰柠檬酰胺
ES2370980T3 (es) Formulación de resagilina de liberación retardada.
US12465570B2 (en) Methods
US8691872B2 (en) Dispersions of rasagiline citrate
MX2013000332A (es) 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-dihidroquinolina-3-ca rboxamida, sales y usos de la misma.
AU2009275665A1 (en) Polymorphic form of rasagiline mesylate
CN104395291B (zh) N‑乙基‑4‑羟基‑1‑甲基‑5‑(甲基(2,3,4,5,6‑五羟基己基)氨基)‑2‑氧代‑n‑苯基‑1,2‑二氢喹啉‑3‑甲酰胺
EP2874628B1 (en) Salts and hydrates of antipsychotics
WO2008066729A2 (en) Boronic acid containing compositions
NZ624206B2 (en) R(+)-n-formyl-propargyl-aminoindan
CN1305491A (zh) 晶体形式的1S－[1a(2S ,3R ),9a]－6,10－二氧代－N－(2－乙氧基－5－氧代－四氢－3－呋喃基)－9[[1－异喹啉基羰基)氨基],八氢－6H－哒嗪并[1,2－A][1,2]二氮杂䓬－1－甲酰胺

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20140618

RJ01 Rejection of invention patent application after publication